Coherus Oncology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M |
| Cost of revenue | $13.8M | $8.7M | $159.0M | $70.1M | $57.6M |
| Selling, general & administrative | $100.6M | $125.5M | $192.0M | $198.5M | $169.7M |
| Research and development | $108.9M | $91.8M | $109.4M | $199.4M | $363.1M |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M |
| Interest expense | $9.0M | $10.7M | $40.5M | $32.5M | $23.0M |
| Pretax income | -$183.1M | -$215.4M | -$238.3M | -$291.8M | -$287.1M |
| Income tax expense | $0 | $0 | -$380,000 | $0 | $0 |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M |
| Balance Sheet | |||||
| Cash and equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M |
| Current assets | $206.7M | $341.6M | $475.6M | $381.2M | $602.3M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M |
| Current liabilities | $140.4M | $283.0M | $331.8M | $138.7M | $165.3M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M |
| Stockholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M |
| Depreciation and amortization | $1.3M | $1.6M | $3.2M | $3.6M | $3.5M |
| Stock-based compensation | $17.0M | $27.8M | $43.1M | $50.7M | $51.4M |
| Capital expenditure | — | — | $286,000 | $2.0M | $1.3M |
| Free cash flow | — | — | -$175.2M | -$243.2M | -$38.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 154.2M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.